PSY Shortwave Life Sciences Plc

TIDMPSY

RNS Number : 3278F

Psych Capital PLC

07 July 2023

7 July 2023

PSYCH CAPITAL PLC

("Psych Capital" or "the Company")

PSYCH Symposium 2023

Industry leaders explored the challenges and opportunities facing the psychedelic industry from clinical trial design to fundraising

On Thursday 6(th) July, Europe's leading event in psychedelic medicine, PSYCH Symposium 2023, returned to London with huge success for the second year running. This year's event featured a range of inspiring speakers and panel discussions with the industry's leading figures, all committed to unlocking the medical and commercial potential of psychedelics.

Stephen Murphy, Founder of PSYCH Symposium, commented: "Once more, PSYCH Symposium has been a resounding success. This is Europe's leading event in psychedelic medicine, and we brought together key stakeholders to explore how we expedite the adoption of psychedelic medicine. This year, we highlighted some of the challenges facing the industry and looked at how to improve the investment and funding landscape. We sought to outline clear treatment and regulatory pathways for the industry as it seeks to evolve and ultimately deliver potentially life-changing medicines to patients in need. It was fantastic to hear from so many of the industry's leading experts and we were delighted to be able to bring everyone together again in such a collaborative environment. I would like to thank everyone for their participation."

This year's event highlights included fireside discussions with Professor Robin Carhart-Harris, Professor of Neurology & Psychiatry, Director Psychedelics Division, Neuroscape at UCSF, in 'Shifting perceptions: Assessing the ways in which psychedelic medicine could help to shape society'; and Christian Angermayer, Founder of Apeiron Investment Group, in 'Reassessing the psychedelic space: What are the realities of the current market?'.

PSYCH Symposium also saw panel discussions on new modalities of treatment, including the potential for psychedelics to treat eating disorders and ketamine-assisted therapy to treat addiction. Medicine regulators from Europe and across the globe also explored the pathways to approval; the importance of building robust regulatory frameworks; and how to prepare national healthcare systems for psychedelic-assisted psychotherapy.

Cybin hosted a discussion with Business Insider, 'Challenges in psychedelic drug development', with Chief Medical Officer, Dr Amir Inamdar, commenting: "We are excited to be at the forefront of innovation in psychedelic medicine, which has the potential to revolutionise treatment of mental health conditions for patients. This year's PSYCH Symposium explored the challenges we face to make this a reality and we were thrilled to sponsor such a successful event."

Building on this, Clerkenwell Health explored the end-to-end process of psychedelic clinical trials, with Chief Commercial Officer George McBride saying, "there are many complexities associated with the psychedelic trial process, understanding this will be crucial for company's ability to succeed."

Rivki Stern, CEO of Shortwave Pharma reflected on her participation at the conference, "It has been such an illuminating and thought-provoking event, and a great opportunity to connect in person with so many industry-leaders. It is clear that the industry is maturing but there are still challenges to overcome on the way to the 'plateau of productivity'".

Negev Capital Partner, Ken Belotsky said: "The psychedelic sector has witnessed a significant milestone, with an astounding 24% of all recent clinical trials for the treatment of depression being based on psychedelic compounds. This remarkable statistic highlights the potential of psychedelic therapy to revolutionise the mental health care system. Negev Capital continues to prioritise investments in leading companies operating within the psychedelics space."

A full list of speakers can be found here .

This year's event was sponsored by Cybin, Shortwave Pharma, Compass Pathways, Negev Capital, Clerkenwell Health, Beautiful Space and FTI Consulting.

-ENDS-

Media inquiries : PsychSymposium@fticonsulting.com

The Directors of the Company accept responsibility for the contents of this announcement.

Enquiries:

Company:

Joseph Colliver: +44 20 3838 7621

William Potts: +44 20 3838 7621

info@psych.capital

https://psych.capital

Peterhouse Capital Limited:

Corporate Adviser:

Guy Miller / Narisha Ragoonanthun: + 44 (0) 20 7469 0930

Corporate Broker

Lucy Williams: +44 (0) 20 7469 0930

Duncan Vasey: +44 (0) 20 7220 9797 (Direct)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXKZGGNVNZGFZG

(END) Dow Jones Newswires

July 07, 2023 03:00 ET (07:00 GMT)

Shortwave Life Sciences (AQSE:PSY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Shortwave Life Sciences (AQSE:PSY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024